Micro-dose latanoprost effective in lowering IOP

A phase 2 study found micro-doses of latanoprost were consistent with standard drops in lowering IOP and were more likely to be successfully administered by subjects, Eyenovia announced in a press release.

Full results of the phase 2 PG21 study, which compared Eyenovia’s 0.4 µg piezo-print micro-dose of latanoprost with standard latanoprost eye drops, were recently published in Clinical Ophthalmology. The micro-dose uses 75% less drug and preservative, the release said.

Subjects using the micro-dose were successful at self-administering the drops 88% of the time compared with less than 50% of the time with standard drops, as reported in other studies.

In addition, the micro-dose subjects achieved a 29% drop in IOP from baseline, which is consistent with the 26% decrease that conventional latanoprost eye drops have shown in other studies.

“In addition to our two previous phase 2 studies in mydriasis, we believe that PG21 further demonstrates that micro-dosing is well tolerated, easily delivered and therapeutically effective without the waste, discomfort and ocular overdosing associated with legacy eye dropper delivery,” Sean Ianchulev, MD, MPH, Eyenovia CEO and chief medical officer, said in the release.

A phase 2 study found micro-doses of latanoprost were consistent with standard drops in lowering IOP and were more likely to be successfully administered by subjects, Eyenovia announced in a press release.

Full results of the phase 2 PG21 study, which compared Eyenovia’s 0.4 µg piezo-print micro-dose of latanoprost with standard latanoprost eye drops, were recently published in Clinical Ophthalmology. The micro-dose uses 75% less drug and preservative, the release said.

Subjects using the micro-dose were successful at self-administering the drops 88% of the time compared with less than 50% of the time with standard drops, as reported in other studies.

In addition, the micro-dose subjects achieved a 29% drop in IOP from baseline, which is consistent with the 26% decrease that conventional latanoprost eye drops have shown in other studies.

“In addition to our two previous phase 2 studies in mydriasis, we believe that PG21 further demonstrates that micro-dosing is well tolerated, easily delivered and therapeutically effective without the waste, discomfort and ocular overdosing associated with legacy eye dropper delivery,” Sean Ianchulev, MD, MPH, Eyenovia CEO and chief medical officer, said in the release.